Literature DB >> 32808161

Prognostic Impact of Histologic Grade for Papillary Thyroid Carcinoma.

Allen S Ho1,2, Michael Luu3,4, Laurel Barrios3, Bonnie L Balzer3,5, Shikha Bose3,5, Xuemo Fan3,5, Evan Walgama3,6, Jon Mallen-St Clair3,6, Usman Alam6, Iram Shafqat6, De-Chen Lin7, Yufei Chen8, Jennifer E Van Eyk9, Ellie G Maghami10, Glenn D Braunstein3,11, Wendy L Sacks3,11, Zachary S Zumsteg12,13.   

Abstract

BACKGROUND: While numerous factors affect prognosis in papillary thyroid carcinoma (PTC), the comparative impact of histologic grade has not been well described. Moreover, indications for external beam radiation therapy (EBRT) remain imprecise. We evaluate clinicopathologic characteristics and outcomes for PTC stratified by grade.
METHODS: We profiled histologic grade for PTC (well differentiated, moderately differentiated, poorly differentiated) via hospital (National Cancer Database) and population-based (Surveillance, Epidemiology, and End Results) registries. Cox regression was used to adjust for clinicopathologic covariates. Statistical interactions between subtypes and the effect of EBRT on survival were assessed.
RESULTS: Collectively, worsening clinicopathologic factors (age, tumor size, extrathyroidal extension, nodal spread, M1 disease) and outcomes (disease-free survival, overall survival) correlated with less differentiated state, across all histologic grades (p < 0.001). Multivariable analysis showed escalating hazard with loss of differentiation relative to well-differentiated PTC (moderately differentiated hazard ratio [HR] 1.21, 95% confidence interval [CI] 1.04-1.41, p = 0.02; poorly differentiated HR 2.62, 95% CI 2.23-3.08, p < 0.001). Correspondingly, greater survival benefit was associated with EBRT for poorly differentiated cases (HR 0.36, 95% CI 0.18-0.72, p = 0.004). This finding was upheld after landmark analysis to address potential immortal time bias (HR 0.37, 95% CI 0.17-0.80, p = 0.01).
CONCLUSIONS: Worsening histologic grade in PTC is independently associated with parallel escalation in mortality risk, on a scale approximating or surpassing established thyroid cancer risk factors. On preliminary analysis, EBRT was associated with improved survival in the most aggressive or least differentiated subvariants. Further investigation is warranted to examine the efficacy of EBRT for select poorly differentiated thyroid carcinomas.

Entities:  

Mesh:

Year:  2020        PMID: 32808161     DOI: 10.1245/s10434-020-09023-2

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  41 in total

1.  Incidence and Mortality Risk Spectrum Across Aggressive Variants of Papillary Thyroid Carcinoma.

Authors:  Allen S Ho; Michael Luu; Laurel Barrios; Irene Chen; Michelle Melany; Nabilah Ali; Chrysanta Patio; Yufei Chen; Shikha Bose; Xuemo Fan; Jon Mallen-St Clair; Glenn D Braunstein; Wendy L Sacks; Zachary S Zumsteg
Journal:  JAMA Oncol       Date:  2020-05-01       Impact factor: 31.777

Review 2.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

3.  Adjuvant External Beam Radiotherapy in Locally Advanced Differentiated Thyroid Cancer.

Authors:  Samantha Tam; Moran Amit; Mongkol Boonsripitayanon; Maria E Cabanillas; Naifa L Busaidy; G Brandon Gunn; Stephen Y Lai; Neil D Gross; Erich M Sturgis; Mark E Zafereo
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2017-12-01       Impact factor: 6.223

Review 4.  Papillary thyroid microcarcinoma: optimal management versus overtreatment.

Authors:  Evan Walgama; Wendy L Sacks; Allen S Ho
Journal:  Curr Opin Oncol       Date:  2020-01       Impact factor: 3.645

Review 5.  Screening for Thyroid Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.

Authors:  Jennifer S Lin; Erin J Aiello Bowles; Selvi B Williams; Caitlin C Morrison
Journal:  JAMA       Date:  2017-05-09       Impact factor: 56.272

6.  Mortality Risk of Nonoperative Papillary Thyroid Carcinoma: A Corollary for Active Surveillance.

Authors:  Allen S Ho; Michael Luu; Cynthia Zalt; Luc G T Morris; Irene Chen; Michelle Melany; Nabilah Ali; Chrysanta Patio; Yufei Chen; Jon Mallen St-Clair; Glenn D Braunstein; Wendy L Sacks; Zachary S Zumsteg
Journal:  Thyroid       Date:  2019-09-24       Impact factor: 6.568

Review 7.  Evolving management considerations in active surveillance for micropapillary thyroid carcinoma.

Authors:  Allen S Ho; Irene Chen; Michelle Melany; Wendy L Sacks
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2018-10       Impact factor: 3.243

8.  Increasing diagnosis of subclinical thyroid cancers leads to spurious improvements in survival rates.

Authors:  Allen S Ho; Louise Davies; Iain J Nixon; Frank L Palmer; Laura Y Wang; Snehal G Patel; Ian Ganly; Richard J Wong; R Michael Tuttle; Luc G T Morris
Journal:  Cancer       Date:  2015-02-24       Impact factor: 6.860

9.  Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system.

Authors:  I D Hay; C S Grant; W F Taylor; W M McConahey
Journal:  Surgery       Date:  1987-12       Impact factor: 3.982

Review 10.  Parallels Between Low-Risk Prostate Cancer and Thyroid Cancer: A Review.

Authors:  Allen S Ho; Timothy J Daskivich; Wendy L Sacks; Zachary S Zumsteg
Journal:  JAMA Oncol       Date:  2019-04-01       Impact factor: 31.777

View more
  8 in total

1.  ASO Author Reflections: Limiting Axillary Surgery for Microinvasive Breast Cancer.

Authors:  Ted A James; Betty Fan
Journal:  Ann Surg Oncol       Date:  2020-06-02       Impact factor: 5.344

2.  Prognostic value of preoperative glucose to lymphocyte ratio in patients with resected pancreatic cancer.

Authors:  Yueming Zhang; Yaolin Xu; Dansong Wang; Tiantao Kuang; Wenchuan Wu; Xuefeng Xu; Dayong Jin; Wenhui Lou
Journal:  Int J Clin Oncol       Date:  2020-09-21       Impact factor: 3.402

3.  ASO Author Reflections: C-Reactive Protein/Lymphocyte Ratio as a Promising Marker for Predicting Survival in Pancreatic Cancer.

Authors:  Zhiyao Fan; Guopei Luo; Yitao Gong; Chen Liu; Xianjun Yu
Journal:  Ann Surg Oncol       Date:  2020-04-08       Impact factor: 5.344

Review 4.  Novel Inhibitor-Based Therapies for Thyroid Cancer-An Update.

Authors:  Maciej Ratajczak; Damian Gaweł; Marlena Godlewska
Journal:  Int J Mol Sci       Date:  2021-10-31       Impact factor: 5.923

Review 5.  Molecular Imaging and Theragnostics of Thyroid Cancers.

Authors:  Luca Giovanella; Desiree' Deandreis; Alexis Vrachimis; Alfredo Campenni; Petra Petranovic Ovcaricek
Journal:  Cancers (Basel)       Date:  2022-03-01       Impact factor: 6.639

6.  Vascular Endothelial Growth Factor Receptor Inhibitors in Chinese Patients With Advanced Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Network Meta-Analysis and Cost-Effectiveness Analysis.

Authors:  Youwen Zhu; Kun Liu; Kailing Wang; Libo Peng
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-14       Impact factor: 6.055

7.  Simple cholecystectomy is an adequate treatment for grade I T1bN0M0 gallbladder carcinoma: Evidence from 528 patients.

Authors:  Jun Shao; Hong-Cheng Lu; Lin-Quan Wu; Jun Lei; Rong-Fa Yuan; Jiang-Hua Shao
Journal:  World J Gastroenterol       Date:  2022-08-21       Impact factor: 5.374

Review 8.  Thyroid Cancers: From Surgery to Current and Future Systemic Therapies through Their Molecular Identities.

Authors:  Loredana Lorusso; Virginia Cappagli; Laura Valerio; Carlotta Giani; David Viola; Luciana Puleo; Carla Gambale; Elisa Minaldi; Maria Cristina Campopiano; Antonio Matrone; Valeria Bottici; Laura Agate; Eleonora Molinaro; Rossella Elisei
Journal:  Int J Mol Sci       Date:  2021-03-18       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.